The BOPA Advanced Pharmacist Training Day June 2025
Overview – This study day is intended to provide an overview of the knowledge, skills, experiences and behaviours required to practice at an advanced level in Cancer Care. The study day…
Read article
Vacancy: BOPA Let’s Communicate Cancer Lead
Vacancy: BOPA Let’s Communicate Cancer Lead Closing Date: 8/6/25 Are you a passionate pharmacy professional with a strong interest in education and training? Do you have the experience and leadership…
Let’s Talk About SACT podcast has been featured in the TOP 40 pharmacology Podcasts worldwide
The BOPA podcast team (Michal Sladkowski, Chiara Creed and Eleanor Meerstadt) are thrilled to share that the Let’s Talk About SACT podcast has been featured in the TOP 40 pharmacology…
NEW eLearning module for Myeloma now live
Dear BOPA members, The Education and Training subcommittee are pleased to announce that our new e-learning module for myeloma is now live on the BOPA website. The module can…
SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment
Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…
Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)
Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…
Women for Oncology UK Spring Webinar
The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…
NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…
Toolkit for Immunotherapy IV to SC switch
Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…
The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back
BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…
Celebration of BOPA member’s recent publications
We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…
HSRPP workshop on conference abstracts
On behalf of the HSRPP Committee, Pharmacy Research UK are delighted to be hosting an online workshop on how to craft a good conference abstract. We will be covering points…